» Articles » PMID: 33603757

Extracellular Vesicles As Inflammatory Drivers in NAFLD

Overview
Journal Front Immunol
Date 2021 Feb 19
PMID 33603757
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent chronic liver disease in most parts of the world affecting one-third of the western population and a growing cause for end-stage liver diseases such as hepatocellular carcinoma (HCC). Majorly driven by obesity and diabetes mellitus, NAFLD is more of a multifactorial disease affected by extra-hepatic organ crosstalk. Non-alcoholic fatty liver (NAFL) progressed to non-alcoholic steatohepatitis (NASH) predisposes multiple complications such as fibrosis, cirrhosis, and HCC. Although the complete pathogenic mechanisms of this disease are not understood, inflammation is considered as a key driver to the onset of NASH. Lipotoxicity, inflammatory cytokines, chemokines, and intestinal dysbiosis trigger both hepatic and systemic inflammatory cascades simultaneously activating immune responses. Over a few years, extracellular vesicles studied extensively concerning the pathobiology of NAFLD indicated it as a key modulator in the setting of immune-mediated inflammation. Exosomes and microvesicles, the two main types of extracellular vesicles are secreted by an array of most mammalian cells, which are involved mainly in cell-cell communication that are unique to cell type. Various bioactive cargoes containing extracellular vesicles derived from both hepatic and extrahepatic milieu showed critical implications in driving steatosis to NASH reaffirming inflammation as the primary contributor to the whole process. In this mini-review, we provide brief insights into the inflammatory mediators of NASH with special emphasis on extracellular vesicles that acts as drivers of inflammation in NAFLD.

Citing Articles

Effects of resveratrol supplementation on serum concentrations of plasminogen activator inhibitor-1, fibroblast growth factor 21, and adiponectin in patients with nonalcoholic fatty liver disease.

Farzin L, Mansouri E, Salehi S, Baker E, Amirkhizi F, Asghari S BMC Nutr. 2025; 11(1):36.

PMID: 39930480 PMC: 11809030. DOI: 10.1186/s40795-025-00997-4.


Metabolic Messengers: small extracellular vesicles.

Rohm T, Cunha E Rocha K, Olefsky J Nat Metab. 2025; 7(2):253-262.

PMID: 39920357 DOI: 10.1038/s42255-024-01214-5.


Chinese herbal formula in the treatment of metabolic dysfunction-associated steatotic liver disease: current evidence and practice.

Tao S, Lei Y, Tan Y, Yang Y, Xie W Front Med (Lausanne). 2024; 11:1476419.

PMID: 39440040 PMC: 11493624. DOI: 10.3389/fmed.2024.1476419.


Emerging roles of RNA-binding proteins in fatty liver disease.

Adesanya O, Das D, Kalsotra A Wiley Interdiscip Rev RNA. 2024; 15(2):e1840.

PMID: 38613185 PMC: 11018357. DOI: 10.1002/wrna.1840.


TACE inhibition: a promising therapeutic intervention against AATF-mediated steatohepatitis to hepatocarcinogenesis.

Srinivas A, Suresh D, Vishwanath P, Satish S, Santhekadur P, Koka S Mol Oncol. 2024; 18(8):1940-1957.

PMID: 38558505 PMC: 11306524. DOI: 10.1002/1878-0261.13646.


References
1.
Lambertucci F, Arboatti A, Sedlmeier M, Motino O, Alvarez M, Ceballos M . Disruption of tumor necrosis factor alpha receptor 1 signaling accelerates NAFLD progression in mice upon a high-fat diet. J Nutr Biochem. 2018; 58:17-27. DOI: 10.1016/j.jnutbio.2018.04.013. View

2.
Raiborg C, Stenmark H . The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins. Nature. 2009; 458(7237):445-52. DOI: 10.1038/nature07961. View

3.
Estes C, Razavi H, Loomba R, Younossi Z, Sanyal A . Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2017; 67(1):123-133. PMC: 5767767. DOI: 10.1002/hep.29466. View

4.
Garcia-Martinez I, Santoro N, Chen Y, Hoque R, Ouyang X, Caprio S . Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9. J Clin Invest. 2016; 126(3):859-64. PMC: 4767345. DOI: 10.1172/JCI83885. View

5.
Moran L, Cubero F . Extracellular vesicles in liver disease and beyond. World J Gastroenterol. 2018; 24(40):4519-4526. PMC: 6209575. DOI: 10.3748/wjg.v24.i40.4519. View